D.E. Shaw & Co
VERA icon

D.E. Shaw & Co’s Vera Therapeutics VERA Stock Holding History

D.E. Shaw & Co’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.2M Buy
74,509
+69,009
+1,255% +$2.57M ﹤0.01% 2787
2026
Q1 		$221K Buy
+5,500
New +$237K ﹤0.01% 4170
2025
Q3 		– Sell
-15,154
Closed -$357K – 4951
2025
Q2 		$357K Buy
+15,154
New +$341K ﹤0.01% 3787
2025
Q1 		– Sell
-74,476
Closed -$3.15M – 4785
2024
Q4 		$3.15M Sell
74,476
-55,990
-43% -$2.48M ﹤0.01% 2360
2024
Q3 		$5.77M Sell
130,466
-240,219
-65% -$9.12M 0.01% 1827
2024
Q2 		$13.4M Sell
370,685
-230,351
-38% -$9.14M 0.01% 1148
2024
Q1 		$25.9M Buy
601,036
+390,997
+186% +$13.9M 0.02% 785
2023
Q4 		$3.23M Buy
210,039
+51,853
+33% +$659K ﹤0.01% 2281
2023
Q3 		$2.17M Buy
+158,186
New +$2.71M ﹤0.01% 2500

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

D.E. Shaw & Co's VERA Position: Q2 2026 in Review

D.E. Shaw & Co increased its Vera Therapeutics (VERA) stake by 1,255% in Q2 2026, buying an estimated $2.57M and bringing the position to 74,509 shares worth $3.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2787.

D.E. Shaw & Co first reported a position in VERA in Q3 2023 and has held it in 9 quarters since. The position peaked at $25.9M in Q1 2024. 220 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • D.E. Shaw & Co held 74,509 shares of Vera Therapeutics worth $3.2M as of Q2 2026.
  • D.E. Shaw & Co bought 69,009 Vera Therapeutics shares in Q2 2026, an estimated $2.57M.
  • Vera Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2787 holding.
  • D.E. Shaw & Co first reported a position in Vera Therapeutics in Q3 2023 and has held it in 9 quarters since.
  • D.E. Shaw & Co's Vera Therapeutics position peaked at $25.9M in Q1 2024.
  • 220 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.